IMU imugene limited

18.2%

1.3¢

It depends on the design of the trial. It could be:- new...

First 134 Last

Share
Profile

Follow
firehawk08

1,853 Posts.

162

06/01/25

16:23

Post #: 77289154
Share

Originally posted by jwt: ↑

Would truly like some imput here. Will people being inducted into the new Oz trials in addition to all those trials being conducted elsewhere be given the "REAL DEAL" or will half of them be given a placebo. I ask because a close friend has been having chemo for many months but the cancer has spread from bowel to liver and elsewhere. Recently, I noticed and met a number of her rellies arriving from all over the world. This tells me I think that time is running out. I want to let her know about trials, if her condition fits, but couldn't do it if 50% of applicants were going to have a placebo. Mind you, I do suppose you would be warned about that possibility and would have to make your own decision. But do any of you know the score here? Thanks.

Expand

It depends on the design of the trial.

It could be:
- new treatment versus placebo
- new treatment versus current standard of care
- new treatment plus current standard of care versus placebo plus current standard of care

You cannot assume that half the participants in the trial are getting a sugar pill.

IMU Price at posting: 4.4¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 134 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.3¢		Change 0.002(18.2%)		Mkt cap ! $97.07M

Open	High	Low	Value	Volume
1.2¢	1.4¢	1.1¢	$625.7K	50.56M

Buyers (Bids)

No.	Vol.	Price($)
20	5795292	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.3¢	3258567	9

View Market Depth

No.	Vol.	Price($)
20	5795292	0.012
39	12054746	0.011
123	37475571	0.010
38	20531668	0.009
14	4320747	0.008

Price($)	Vol.	No.
0.013	3258567	9
0.014	11336079	44
0.015	6830166	21
0.016	6274494	28
0.017	7081669	12

Last trade - 16.10pm 27/06/2025 (20 minute delay)

IMU (ASX) Chart

It depends on the design of the trial. It could be:- new...

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It depends on the design of the trial. It could be:- new...

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News